Sunharbo (asundexian)
Bayer HealthCare Pharmaceuticals
ApprovedNov 9, 2026
Marketer take
Opens a new drug class in secondary stroke prevention, so neurology and cardiology brand teams should expect new HCP education needs and competitive messaging around antiplatelet regimens.
- Sponsor company
- Bayer HealthCare Pharmaceuticals
- Indication
- To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
- Therapeutic area
- Cardiovascular, Neurology
- Event
- FDA approval
- Date
- Nov 9, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?